An Innovative Probiotic Product With Antiallergic Properties

Status Completed

Clinical Trial Summary

Allergic diseases are currently one of the most important problem in medicine. Research confirms that probiotics administered during the formation of the intestinal ecosystem and the maturation of the immune system can positively influence the development of antiallergic mechanisms. The aim of the present randomized, double-blind, placebo controlled study was to evaluate the efficacy of the mixture of probiotic Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908, and Lactobacillus casei ŁOCK 0919 in children up to the age 2 with atopic dermatitis and food allergy to cow's milk proteins. Children received the mixture of Lactobacillus strains for 3 months every day in the daily dose of a billion bacteria or a placebo (maltodextrin). Primary outcomes included the effects of probiotic treatment on the severity of symptoms assessed with SCORing atopic dermatitis (SCORAD) index. Secondary endpoints included assessment of total IgE and selected cytokine levels. Cytokines were evaluated in supernatants obtained from peripheral blood cultures of randomly selected 20 patients from each group. The primary and secondary outcomes were assessed at 3 time points: at baseline, after the finishing the administration of probiotic/placebo, and after 9 months of follow up.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04738565
Study type	Interventional
Source	Children's Memorial Health Institute, Poland
Contact
Status	Completed
Phase	N/A
Start date	June 1, 2012
Completion date	December 31, 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05018806` - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis	Phase 2
Terminated	`NCT03847389` - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis	Phase 1/Phase 2
Completed	`NCT04090229` - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis	Phase 1
Active, not recruiting	`NCT05388760` - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)	Phase 2
Completed	`NCT05530707` - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer	N/A
Completed	`NCT02595073` - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis	Phase 3
Recruiting	`NCT05509023` - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)	Phase 2
Recruiting	`NCT05048056` - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis	Phase 2
Completed	`NCT04598269` - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis	Phase 2
Recruiting	`NCT03936335` - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn	`NCT03089476` - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy	N/A
Recruiting	`NCT05029895` - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated	`NCT03654755` - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis	Phase 2
Completed	`NCT04556461` - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function	Phase 2
Recruiting	`NCT04818138` - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort	N/A
Completed	`NCT03719742` - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer	N/A
Completed	`NCT05375955` - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.	Phase 2
Completed	`NCT03441568` - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control	N/A
Recruiting	`NCT06366932` - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models	Phase 4
Completed	`NCT03304470` - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis	Phase 2